Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Oncology, Hikma, Excellmab, Dr. Reddy’s, Apotex, LEO Pharma - LARVOL DELTA

Prolonged Progression-Free Survival in a Patient with Highly Pretreated Recurrent Ovarian Cancer after Developing Multisystem Immune-Related Adverse Events: A Case Report and Literature Review. (PubMed, Case Rep Oncol) - "Between 2013 and 2021, she underwent palliative chemotherapy comprising paclitaxel liposomes, cisplatin/nedaplatin, S-1/raltitrexed, irinotecan, doxorubicin, vinorebine, toripalimab, apatinib, gemcitabine, oxaliplatin, and capecitabine, as well as two debulking surgeries. From November 2021, she received six cycles of tislelizumab (a PD-1 inhibitor), paclitaxel (albumin-bound), and carboplatin, to which a partial response was observed according to the Response Evaluation Criteria in Solid Tumors. From May 2022, the patient was switched to maintenance therapy with tislelizumab plus olaparib...We report a case involving a patient with highly pretreated recurrent ovarian cancer who exhibited prolonged PFS after developing three irAEs. The distinctly prolonged PFS observed, along with the reviewed literature, suggests that irAEs may be correlated with improved survival in ovarian cancer."

Adverse events • IO biomarker • Journal • Tumor mutational burden • Endocrine Disorders • Gynecology • Microsatellite Instability • Nephrology • Obstetrics • Oncology • Ovarian Cancer • Pneumonia • Renal Disease • Solid Tumor • MSI • TMB

Successful treatment of advanced Birt-Hogg-Dubé syndrome-associated renal cell carcinoma with sarcomatoid dedifferentiation using anlotinib combined with PD-1 inhibitor after first-line therapy failure: a case report. (PubMed, World J Surg Oncol) - "This case not only reveals the complexity and treatment challenges of BHD syndrome-associated renal cell carcinoma with sarcomatoid dedifferentiation but also provides an important basis for the development of individualized treatment strategies. The successful treatment of this case suggests that targeted immunotherapy may have potential advantages in refractory cases and emphasizes the important role of gene testing in guiding individualized treatment. In the future, it is necessary to further explore the molecular mechanism of BHD syndrome-associated renal cell carcinoma and sarcomatoid renal cell carcinoma and verify the efficacy of targeted immunotherapy."

IO biomarker • Journal • Genetic Disorders • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Respiratory Diseases • Sarcoma • Solid Tumor • BRCA2 • FLCN • MME • VIM

Neoadjuvant and Adjuvant Toripalimab and Cetuximab in Patients With Recurrent, Resectable Squamous Cell Carcinoma of Head and Neck: a Prospective, Single-arm,Phase II Study (clinicaltrials.gov) - P2 | N=52 | Active, not recruiting | Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2026 ➔ Apr 2026 | Trial primary completion date: Jan 2024 ➔ Apr 2025

Enrollment closed • Trial completion date • Trial primary completion date • Head and Neck Cancer • Oncology • Oropharyngeal Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • PD-L1

Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC (clinicaltrials.gov) - P2 | N=39 | Recruiting | Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

New P2 trial • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Focus on PD-1/PD-L1-Targeting Antibodies in Colorectal Cancer: Are There Options Beyond Dostarlimab, Nivolumab, and Pembrolizumab? A Comprehensive Review. (PubMed, Molecules) - "However, a growing number of additional PD-1/PD-L1 inhibitors, including AMP-224, atezolizumab, avelumab, camrelizumab, durvalumab, envafolimab, sintilimab, spartalizumab, tislelizumab, and toripalimab, are currently under investigation, offering new possibilities for the expansion of treatment options...Additionally, it explores key challenges such as primary and acquired resistance, limited efficacy in microsatellite-stable (MSS) CRC, and the complexities of combination strategies aimed at enhancing immunotherapeutic responses. By addressing these obstacles and highlighting prospects, this review provides insights into the evolving landscape of PD-1/PD-L1-targeted therapies in CRC and their potential to improve patient outcomes."

Journal • Review • Colorectal Cancer • Oncology • Solid Tumor • MSI

Efficacy and safety of immunotherapy or antiangiogenic agent-based treatment strategies versus chemotherapy as first-line treatment for extensive-stage small cell lung cancer: a network meta-analysis. (PubMed, Front Pharmacol) - "Immune checkpoint inhibitors (ICIs) combined with etoposide-platinum are recommended as the standard first-line therapy for extensive-stage small cell lung cancer (ES-SCLC)...The drug combination patterns included ipilimumab, durvalumab, adebrelimab, atezolizumab, socazolimab, pembrolizumab, serplulimab, tislelizumab, toripalimab, durvalumab + tremelimumab, tiragolumab + atezolizumab, benmelstobart + anlotinib, bevacizumab + atezolizumab, anlotinib, bevacizumab in combination with chemotherapy...The toxicity of ICI + Antiangio + Chemo was acceptable but needed careful attention. These findings clarified the roles of ICIs and antiangiogenic agent-based treatment strategies in this population."

Journal • Retrospective data • Review • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Network meta-analysis of perioperative immunotherapies in non-small-cell lung cancer according to tumor programmed death ligand 1 expression. (PubMed, Farm Hosp) - "Our network meta-analysis provides reliable evidence on the efficacy of perioperative immunotherapy in resectable NSCLC according to PD-L1 expression levels, and may favor competition between therapeutic alternatives. A sensitivity analysis supported these results."

IO biomarker • Journal • Retrospective data • Review • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

Induction Immunotherapy Combined With Chemotherapy Followed by Concurrent Chemoradiotherap and Immunotherapy for Cervical Cancer (clinicaltrials.gov) - P2 | N=34 | Recruiting | Sponsor: Tianjin Medical University Cancer Institute and Hospital

New P2 trial • Cervical Cancer • Oncology • Solid Tumor

Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma (clinicaltrials.gov) - P=N/A | N=98 | Not yet recruiting | Sponsor: Sichuan University

New trial • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

KEYNOTE-C16: Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=260 | Active, not recruiting | Sponsor: Coherus Biosciences, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Hepatocellular Cancer • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

Unveiling the best immune checkpoint inhibitor-based therapy for metastatic renal cell carcinoma in the first-line setting: an updated systematic review and Bayesian network analysis. (PubMed, Ther Adv Med Oncol) - "Our findings demonstrated that combination therapies including nivolumab plus cabozantinib, pembrolizumab plus lenvatinib, toripalimab plus axitinib, nivolumab plus ipilimumab, pembrolizumab plus axitinib, and avelumab plus axitinib significantly improved OS versus sunitinib. For subgroup analysis, ICI-based combination therapies exhibited significant advantages over sunitinib for intermediate-risk or poor-risk patients, while such advantages were diminished in treating favorable-risk patients."

Checkpoint inhibition • Journal • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

A Safety, Feasibility, and Efficacy Study of Gemcitabine Plus Docetaxel Plus Toripalimab (GDT) Induction as Part of a Curative Sequential Chemoradiation for Patients with Locoregional EBV-Associated Nasopharyngeal Carcinoma (NPC) (ESMO 2025) - No abstract available

Clinical • Nasopharyngeal Carcinoma • Oncology • Solid Tumor

Bulumtatug Fuvedotin (BFv; 9MW2821), a novel Nectin-4 antibody-drug conjugate(ADC), combined with Toripalimab in patients with locally advanced or metastatic urothelial carcinoma(la/mUC): Follow-up results from a phase 1b/2 study. (ESMO 2025) - No abstract available

Clinical • Metastases • P1/2 data • Oncology • Solid Tumor • Urothelial Cancer

Changes in Circulating Tumor Cells (CTCs) and HER-2 Expression as Indicators of Efficacy and Recurrence Prediction in Neoadjuvant Disitamab Vedotin (DV) Plus Toripalimab Treatment for Muscle-Invasive Bladder Cancer (MIBC): Updated Data and Preliminary Outcomes for Recurrence (ESMO 2025) - No abstract available

Circulating tumor cells • Clinical • Tumor cell • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • CTCs • HER-2

A Prospective Interventional Study of Preoperative PD-1 Monoclonal Antibody (Toripalimab) Combined with Gemcitabine and Albumin-bound Paclitaxel for Borderline Resectable and Locally Advanced Pancreatic Cancer (ESMO 2025) - No abstract available

Clinical • Metastases • Oncology • Pancreatic Cancer • Solid Tumor

A phase II, open-label study of toripalimab, cetuximab plus FOLFIRI as first-line treatment of unresectable left-sided RAS/BRAF wild-type metastatic colorectal cancer (Tesla study) (ESMO 2025) - No abstract available

Clinical • Metastases • P2 data • Colorectal Cancer • Oncology • Solid Tumor • BRAF • RAS

Chemotherapy plus Toripalimab as Neoadjuvant Therapy for Locally Advanced Upper Tract Urothelial Carcinoma: Mid-term Results from the Phase II, Multi-center Study (WUTSUP-01) (ESMO 2025) - No abstract available

Clinical • Metastases • P2 data • Oncology • Solid Tumor • Urothelial Cancer

Final Analysis and Biomarker Evaluation of JUPITER-06: A Phase 3 Trial of Toripalimab Plus Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESMO 2025) - No abstract available

Biomarker • Metastases • P3 data • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

Phase 1b trial of toripalimab combined with anlotinib and stereotactic body radiotherapy in patients with untreated oligometastatic brain metastases of driver mutation-negative non-small cell lung cancer (NSCLC) (ESMO 2025) - No abstract available

Clinical • Metastases • P1 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Surufatinib combined with Toripalimab, Pemetrexed, and Platinum in Advanced Non-Squamous Non-Small Cell Lung Cancer (nsq-NSCLC): Final Phase II Results from a Single-Center Trial (ESMO 2025) - No abstract available

Clinical • Metastases • P2 data • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Toripalimab Plus Bevacizumab and Chemoradiotherapy as Treatment in Patients With Advanced Melanoma: The IRAC Phase 2 Nonrandomized Clinical Trial (ESMO 2025) - No abstract available

Clinical • Metastases • P2 data • Melanoma • Oncology • Solid Tumor

DNV3 Plus Toripalimab and Chemotherapy in Advanced Melanoma: An update on an Open-Label Investigator-initiated Trial (ESMO 2025) - No abstract available

Clinical • Metastases • Melanoma • Oncology • Solid Tumor

Neoadjuvant Chemotherapy Plus Toripalimab for Larynx Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial (ESMO 2025) - No abstract available

Clinical • Metastases • P2 data • Head and Neck Cancer • Hypopharyngeal Cancer • Oncology • Solid Tumor

Efficacy Of The TLR7 Agonist CAN1012 Alone Or Combined With The Anti-PD-1 Antibody Toripalimab (ESMO 2025) - No abstract available

Clinical • Oncology

Phase I study of ARX788 plus toripalimab in advanced solid tumors with expansion in HER2-low advanced breast cancer. (ESMO 2025) - No abstract available

Metastases • P1 data • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2